TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35379815
Drug: BBIBP-CorV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBIBP-CorV vaccine
Study: 35379845
Drug: Antifolate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifolate therapy
Study: 35379979
Drug: Intravitreal sepofarsen
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal sepofarsen 160 µg/80 µg
Study: 35379979
Drug: Intravitreal sepofarsen
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal sepofarsen 320 µg/160 µg
Study: 35380627
Drug: Eating breakfast
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating breakfast daily
Study: 35382436
Drug: sMRI-guided radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sMRI-guided radiation therapy (RT) dose escalation to 75 Gy
Study: 35382436
Drug: sMRI-guided RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sMRI-guided RT dose escalation to 75 Gy
Study: 35383069
Drug: Computerised-decision support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised-decision support system (CDSS) for antibiotic stewardship (APSS) and electronic surveillance software (ESS) for infection surveillance (ZINC)
Study: 35383088
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention with 2 weekly text messages for 3 months after CR completion.
Study: 35383117
Drug: Abatacept (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (60 mg/kg in three doses of 20 mg/kg each within the first 10 days, followed by two doses) combined with ruxolitinib and methylprednisolone
Study: 35383117
Drug: Corticosteroids and
Normalized name: Corticosteroids and mydriatics in combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids and mycophenolate-mofetil (initial treatment before abatacept)
Study: 35383374
Drug: Cefotaxime 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 150 mg/kg/day (interval 6-8 h)
Study: 35383374
Drug: Cefotaxime 200
Normalized name: cefotaxime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 200 mg/kg/day (interval 6 h)
Study: 35383374
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose followed by continuous infusion regimens
Study: 35383885
Drug: Zanubrutinib 320
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 320 mg once daily (QD)
Study: 35383885
Drug: Zanubrutinib 160
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanubrutinib 160 mg twice daily (BID)
Study: 35385466
Drug: Multisensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory stimulation (MSS) and soft tissue therapy (STT) for 5 consecutive days
Study: 35385480
Drug: Rivaroxaban initiated
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban initiated < 72 hours after reperfusion therapy
Study: 35385480
Drug: Rivaroxaban initiated
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban initiated ≥ 72 hours after reperfusion therapy
Study: 35385922
Drug: Nilotinib (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (initial dose 400 mg twice daily, later reduced to 300 mg twice daily)
Study: 35385993
Drug: Tepotinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tepotinib (oral MET kinase inhibitor)
Study: 35386419
Drug: Vagal Nerve
Normalized name: gammaCore Vagal Nerve Stimulator for Headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagal Nerve Stimulation (VNS) therapy
Study: 35386419
Drug: Statistical model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical model for prediction of response to VNS therapy
Study: 35386508
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels 1-3 mg/L
Study: 35386508
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels >3-10 mg/L
Study: 35386508
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels >10 mg/L
Study: 35386508
Drug: hs-CRP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP levels <1 mg/L
Study: 35386606
Drug: Fluoxetine 90
Normalized name: fluoxetine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 90 mg once weekly for 10 weeks (increased to 180 mg once weekly if inadequate response)
Study: 35386606
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily for 2 weeks (initial tolerance assessment)
Study: 35387414
Drug: Preoperative Stereotactic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Stereotactic Body Radiation Therapy (SBRT) - 35 to 40 Gy in 5 fractions every other day
Study: 35387421
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (60 Gy in 30 fractions for PET responders)
Study: 35387421
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation (74 Gy in 30 fractions for nonresponders)
Study: 35387421
Drug: Platinum-doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-doublet chemotherapy concurrent with 6 weeks of radiation
Study: 35387589
Drug: Perturbed walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perturbed walking with a concurrent cognitive task
Study: 35388003
Drug: Ramucirumab (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (an anti-VEGFR2 monoclonal antibody)
Study: 35388792
Drug: Monodisciplinary inclusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monodisciplinary inclusive work measures (treatment as usual)
Study: 38017325
Drug: EMI-137 (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMI-137 (0.13 mg/kg)
Study: 35391576
Drug: Chemotherapy/immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/immunotherapy
Study: 35393425
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m²)
Study: 35394445
Drug: Tablet computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer-based remote patient monitoring system
Study: 35395574
Drug: Nurses' pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses' pain assessment before analgesic consumption
Study: 35395574
Drug: Nurses' pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurses' pain assessment 1 hour after analgesic consumption
Study: 35395574
Drug: Agreement between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement between children's and nurses' pain scores before analgesic consumption
Study: 35395574
Drug: Agreement between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement between children's and nurses' pain scores 1 hour after analgesic consumption
Study: 35395574
Drug: Agreement between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement between children's and parents' pain scores before analgesic consumption
Study: 35395574
Drug: Agreement between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agreement between children's and parents' pain scores 1 hour after analgesic consumption
Study: 35395680
Drug: Entrectinib (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib (oral, once-daily)
Study: 35396138
Drug: PDR-/HDR-brachytherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR-/HDR-brachytherapy as boost after external beam radiation therapy up to a total dose of 91-96 Gy (EQD2, α/β = 3 Gy)
Study: 35396138
Drug: PDR-/HDR-brachytherapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR-/HDR-brachytherapy with simultaneous integrated focal boost to intra-prostatic tumor lesions up to a total dose of 108-119 Gy (EQD2, α/β = 3 Gy)
Study: 35396812
Drug: Talazoparib 250mcg
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 250mcg daily with carboplatin AUC5-6 and paclitaxel 80 mg/m²
Study: 35396812
Drug: Talazoparib 250mcg
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 250mcg on a 3- or 7-day schedule with carboplatin AUC6 and paclitaxel 80 mg/m²
Study: 35397434
Drug: Gatipotuzumab (1400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatipotuzumab (1400 mg every 2 weeks) combined with tomuzotuximab (1200 mg every 2 weeks)
Study: 35401389
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training during chemotherapy
Study: 35401389
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line chemotherapy without exercise training
Study: 39632341
Drug: LEM 5
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LEM 5 mg
Study: 35403786
Drug: Microneedling procedures
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Microneedling procedures (4 monthly sessions)
Study: 35404402
Drug: Adagrasib (MRTX849)
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib (MRTX849) 600 mg twice daily
Study: 35404455
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk (HM) insulin concentrations
Study: 35404683
Drug: 21-gene expression
Normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21-gene expression assay (recurrence score [RS]) and response to 3-week preoperative endocrine therapy (ET)
Study: 35404683
Drug: Guiding systemic
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guiding systemic treatment by both RS and ET response
Study: 35404977
Drug: Community-based cross-sectional
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Community-based cross-sectional study with self-reported survey and oral fluid testing for HIV antibodies.
Study: 35405360
Drug: Crizotinib treatment
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib treatment with low PD-L1 expression (TPS < 50%)
Study: 35405360
Drug: Crizotinib treatment
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib treatment with high PD-L1 expression (TPS ≥ 50%)
Study: 35406491
Drug: Pre-chemotherapy CA27.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy CA27.29 assessment
Study: 35406491
Drug: Post-chemotherapy CA27.29
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy CA27.29 assessment
Study: 35407553
Drug: Edoxaban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (60 mg daily for 23 patients, 30 mg daily for 2 patients)
Study: 35407655
Drug: Daily bedside
Normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily bedside echocardiographic monitoring (JetEcho)
Study: 35410197
Drug: Oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronate 150 mg once monthly for 1 year
Study: 35410326
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of alcohol/drugs prior to intercourse (sometimes)
Study: 35410326
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of alcohol/drugs prior to intercourse (always)
Study: 35410326
Drug: Any HIV
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any HIV treatment literacy
Study: 35410449
Drug: CoMDA-ML (Quadratic
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoMDA-ML (Quadratic Discriminant Analysis algorithm)
Study: 35410912
Drug: Body iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body iron stores (BIS) measured by serum ferritin and serum transferrin receptor
Study: 35410912
Drug: Daily smoking,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily smoking, hypertension, and increased resting heart rate
Study: 35412069
Drug: Mirabegron treatment
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron treatment for UUI
Study: 35412216
Drug: batoclimab 680
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batoclimab 680 mg
Study: 35412216
Drug: batoclimab 340
Normalized name: Batoclimab
DrugBank: Batoclimab (DB16104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: batoclimab 340 mg
Study: 35412356
Drug: Camostat mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate 200 mg dosed four times daily
Study: 35412356
Drug: Camostat mesylate
Normalized name: camostat mesylate
DrugBank: Camostat (DB13729)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camostat mesylate at 3-fold higher dosing
Study: 35413092
Drug: Romiplostim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (1 μg/kg titrated to 10 μg/kg, administered weekly)
Study: 35413279
Drug: Defibrotide (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (6.25 mg/kg/dose IV q6h) for 7 days
Study: 35413794
Drug: hs-cTnT ≥14
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT ≥14 ng/L
Study: 35413794
Drug: hs-cTnT <14
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT <14 ng/L
Study: 35413794
Drug: NT-proBNP ≥300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP ≥300 pg/ml
Study: 35413794
Drug: NT-proBNP <300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP <300 pg/ml
Study: 35413794
Drug: Both hs-cTnT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both hs-cTnT ≥14 ng/L and NT-proBNP ≥300 pg/ml
Study: 35414025
Drug: Small-molecule compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule compounds targeting regulated cell death (RCD) subroutines, including narciclasine, torin-1 combined with chloroquine, ONC201, and NCT03733119.
Study: 35414591
Drug: Enoblituzumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoblituzumab (15 mg/kg) plus pembrolizumab (2 mg/kg) every 3 weeks
Study: 35416053
Drug: Avelumab maintenance
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab maintenance treatment plus best supportive care
Study: 35416669
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor and palbociclib
Study: 35416710
Drug: Nifurtimox (NF)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox (NF) treatment
Study: 35417089
Drug: Echocardiographic red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echocardiographic red flags for AC (apical sparing or a combination of ≥2 other red flags)
Study: 35417530
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of HDAC inhibitors (panobinostat or romidepsin) and ClpP activators (ONC206 and ONC212)
Study: 35417530
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of HDAC inhibitors and imipridones
Study: 35417637
Drug: Rilzabrutinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib (200 mg once daily, 400 mg once daily, 300 mg twice daily, 400 mg twice daily)
Study: 35417637
Drug: Rilzabrutinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib (400 mg twice daily)
Study: 35417637
Drug: Rilzabrutinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilzabrutinib (all dose levels)
Study: 35417638
Drug: Mitapivat (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily)
Study: 35418154
Drug: Watch antibiotics
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watch antibiotics (e.g., ceftriaxone, ciprofloxacin)
Study: 35418154
Drug: Watch antibiotics
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watch antibiotics
Study: 35418154
Drug: Access antibiotics
Normalized name: ACCESS PIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access antibiotics
Study: 35418159
Drug: C1M in
Approvals — FDA: no, EMA: no, PMDA: no
Description: C1M in mice treated with CP17 (neutrophil infiltration inhibitor)
Study: 35418329
Drug: Vaginal pH
Normalized name: Azo Vaginal pH Test Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal pH modulator (VPM; Phexxi)
Study: 35418436
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine awareness and acceptance
Study: 35418436
Drug: Perceived effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived effectiveness and safety of COVID-19 vaccines
Study: 35418586
Drug: Nonstandard wearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonstandard wearing of face masks, longer time of face mask wearing, reduced outdoor time, decreased daily reading time, shortened visual display terminals time, dry environment
Study: 35419649
Drug: Usual pNET
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual pNET treatments (chemotherapies and somatostatin analogues)
Study: 35420493
Drug: Tebipenem pivoxil
Normalized name: tebipenem pivoxil
DrugBank: Tebipenem pivoxil (DB16840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tebipenem pivoxil hydrobromide (TBP-PI-HBr); specific dosage and duration not mentioned.
Study: 35420628
Drug: Cabozantinib, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib, 60 mg orally once daily until disease progression, unacceptable toxic effects, or withdrawal of consent.
Study: 35421287
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine system, details on dosage and duration not available
Study: 35422607
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (IVT-AFL) with sham laser
Study: 35422607
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (IVT-AFL) with micropulse (MP) laser
Study: 35425788
Drug: DHA (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (800 mg/day) and EPA (25 mg/day) supplementation for 6 months
Study: 35425930
Drug: Ketogenic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Study: 35425930
Drug: Standard high-carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-carbohydrate diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Study: 35425985
Drug: Doravirine 100
Normalized name: doravirine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine 100 mg once daily added to stable combined ART for 5 days
Study: 35426046
Drug: Other options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other options (other G-CSF or none)
Study: 35427833
Drug: Poststudy salvage
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Poststudy salvage treatment
Study: 35428211
Drug: IV injection
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV injection of low activity benzamide-based radioligands targeting melanin
Study: 35428346
Drug: Dual-tDCS during
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-tDCS during physical therapy (2 mA for 20 minutes)
Study: 35428657
Drug: Autologous, ex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous, ex vivo expanded Tregs infusion (1×10^6 cells)
Study: 35429115
Drug: Circulating proteins
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating proteins related to adipokine signaling and vascular function (e.g., leptin, vascular endothelial growth factor) in women
Study: 35429115
Drug: Circulating proteins
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating proteins related to extracellular matrix organization and inflammation (e.g., matrix metalloproteinase-2, C-reactive protein) in men
Study: 35429329
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg daily), Dexamethasone (20-40 mg weekly), Daratumumab (16 mg/kg)
Study: 35429391
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m2) and Carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles
Study: 35429391
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Carboplatin chemotherapy
Study: 35430299
Drug: Combination immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination immunotherapy for HCC
Study: 35431912
Drug: Psilocybin Assisted
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin Assisted Therapy